PubMed Health⌕ Search

Biomedical subjects

S M Roberts

Publications and source records attributed to S M Roberts.

At least 19 recordsLinked to original sources
PubMed1995

Mechanistic studies on the potentiation of carbon tetrachloride hepatotoxicity by methamphetamine.

Recent studies have shown that methamphetamine is capable of potentiating the hepatotoxicity of carbon tetrachloride in mice. In the present study, it was found that this potentiation is sensitive to changes in the timing of the methamphetamine dose relative to the administration of carbon tetrachloride. Potentiation of hepatotoxicity, measured using serum alanine aminotransferase (ALT) activity, was observed only if the dose of methamphetamine (15 mg/kg, i.p.) was given with, or 3 h after, the carbon tetrachloride dose (0.005 ml/kg, i.p.). No increase in carbon tetrachloride hepatotoxicity was evident when methamphetamine was administered 3 h before the carbon tetrachloride dose, or when given 6 or more hours after carbon tetrachloride. Increased covalent binding of carbon tetrachloride to proteins and lipids, shown previously to occur when methamphetamine and carbon tetrachloride are administered together, was not observed when methamphetamine was administered 3 h after the carbon tetrachloride dose and could not, therefore, account for the increased toxicity resulting from this treatment regimen. Pretreatment with the Kupffer cell inhibitor gadolinium chloride (10 mg/kg, i.v.) significantly diminished the potentiation of carbon tetrachloride hepatotoxicity by methamphetamine, suggesting that potentiation by methamphetamine involves, at least in part, a stimulation of Kupffer cells. Mice administered a methamphetamine pretreatment regimen known to induce behavioral sensitization displayed an enhanced potentiation of carbon tetrachloride hepatotoxicity, i.e. the extent of potentiation by methamphetamine was increased and the methamphetamine dose required for potentiation was diminished. Mice pretreated with a methamphetamine sensitization regimen were also found to be more responsive to the effects of morphine to enhance carbon tetrachloride hepatotoxicity. These observations suggest that there are important CNS, as well as hepatic, components in the potentiation of carbon tetrachloride-induced liver injury by methamphetamine and perhaps other drugs.

Alanine Transaminase↗
PubMed1995

Influence of soil half-life on risk assessment of carcinogens.

Risk estimates for contaminants in soil are currently calculated assuming that concentrations remain unchanged over time. In reality, biological and physicochemical processes can substantially diminish contaminant concentrations in soil. For exposure periods typically evaluated in USEPA risk assessments, failure to consider the decline in contaminant levels from environmental transport and degradation can result in a significant overestimation of the average daily dose of toxicant. This overestimation may be up to 2- to 3-fold for compounds with long half-lives (15-20 years) in soil and as much as 40-fold for compounds with short half-lives (0.5 years). Overestimation of dosages affects estimation of cancer risks because of the assumption that the probability of cancer increases directly with the cumulative dose of carcinogen. Thus, assuming static contaminant concentrations in soil adds unacknowledged conservatism to cancer risk estimates and target concentration limits. Furthermore, as significant time may elapse before future-use scenarios could possibly occur, soil half-life can affect the estimation of noncarcinogenic health hazards as well. Therefore, an increase in target concentration limits for some compounds could be allowed and corresponding remediation costs reduced by considering how soil half-life changes the dosage calculation. Specific examples of the influence of soil degradation rates on estimates of cancer risk are presented and the degree of added conservatism imparted to risk assessments through assumption of static site contaminant levels is discussed. Considering the potential importance of this parameter for risk assessment and risk management decisions, soil degradation of contaminants under site-specific conditions should be performed whenever possible and incorporated into the risk assessment exercise. When the soil degradation rate cannot be measured or reliably predicted, an estimate of the degree of conservatism should be made to provide risk managers with an appreciation of the degree of uncertainty in the calculation of risk.

Animals↗
PubMed1995

Exacerbation of carbon tetrachloride-induced liver injury in the rat by methamphetamine.

The effect of methamphetamine cotreatment on carbon tetrachloride-induced liver toxicity was examined in male Sprague-Dawley rats. Concurrent administration of methamphetamine was found to greatly increase the extent of liver injury resulting from carbon tetrachloride treatment, as indicated both by measurement of serum alanine aminotransferase (ALT) activity and from direct histopathologic examination. Concurrent administration of methamphetamine doses less than 10 mg/kg (i.p.), or administration of methamphetamine either before (-3 h) or after (3-9 h) the carbon tetrachloride dose, did not significantly increase liver injury from carbon tetrachloride. These observations indicate that the potentiation by methamphetamine of carbon tetrachloride hepatoxicity previously observed in the mouse also occurs in the rat, and that the timing of the methamphetamine and carbon tetrachloride doses is critical for the interaction.

Alanine Transaminase↗
PubMed1995

Ocular manifestations of diabetes mellitus: diabetic cataracts in dogs.

Cataracts form in diabetic dogs because of the disruption of normal lens metabolism. The pathophysiology seems to be a combination of increased lens cell membrane permeability, reduced cell membrane function, damage from accumulating osmotic products (polyols), glycosylation of lens proteins, and oxidative injury. Lens-induced uveitis must be recognized and managed in presurgical preparation of dogs with diabetes cataracts. Phacoemulsification is the current treatment of choice for diabetic cataracts in dogs and can be performed at an earlier time than traditional extracapsular lens extraction. This may allow for greater success rates after surgery.

Animals↗
PubMed1995

Pharmacological and biochemical analysis of FPL 67156, a novel, selective inhibitor of ecto-ATPase.

1. FPL 67156 (6-N,N-diethyl-beta, gamma-dibromomethylene-D-ATP), is a newly synthesized analogue of ATP. 2. In a rabbit isolated tracheal epithelium preparation, measuring P2U-purinoceptor-dependent chloride secretion, FPL 67156 was discovered to potentiate the responses to UTP but not those to ATP-gamma-S. UTP agonist-concentration effect (E/[A]) curves were shifted to the left by 5-fold in the presence of 100 microM FPL 67156. The differential effect of FPL 67156 on UTP and ATP-gamma-S was hypothesized to be due to the greater susceptibility of UTP to enzymatic dephosphorylation and the ability of FPL 67156 to inhibit this process. 3. FPL 67156 was tested as an ecto-ATPase inhibitor in a human blood cell assay, measuring [gamma 32P]-ATP dephosphorylation. The compound inhibited [gamma 32P]-ATP degradation with a pIC50 of 4.6. 4. FPL 67156 was then tested for its effects on ATP and alpha, beta-methylene-ATP responses at P2X-purinoceptors in the rabbit isolated ear artery. In the concentration range 30 microM-1 mM, the compound potentiated the contractile effects of ATP but not those of alpha, beta-methylene-ATP. At 1 mM, FPL 67156 produced a 34-fold leftward shift of ATP E/[A] curves. 5. The effects of FPL 67156 on ATP E/[A] curves in the rabbit ear artery were analyzed using a theoretical model (Furchgott, 1972) describing the action of an enzyme inhibitor on the effects of a metabolically unstable agonist. This analysis provided an estimate of the pKi for FPL 67156 as an ecto-ATPase inhibitor of 5.2. 6. Using appropriate assays, FPL 67156 was shown to have weak antagonist effects at P2X- and P2T-purinoceptors (pA2 ~ 3.3 and 3.5 respectively), and weak agonist effects at P2u-purinoceptors(p[A 50]~ 3.5).7. The degree of potentiation of ATP and UTP effects elicited by FPL 67156 confirms previous results concerning the influence that ecto-ATPase has on the position of E/[A] curves for metabolically unstable agonists. The magnitude of this influence is predicted to have a major effect on the agonist potency orders currently used to designate purinoceptors.8.This study indicates FPL 67156 to be a potentially valuable probe in studies on the action of nucleotides and in the classification of purinoceptors.

Adenosine Triphosphatases↗
PubMed1995

Applicability of the goodness-of-fit hypothesis to coping with daily hassles.

This study examined the applicability of Lazarus and Folkman's (1984) goodness-of-fit hypothesis to the relationship between college students' daily hassles and psychological symptomology. Specifically, the model predicts that, given a daily hassle which one may change, it is more functional to alter the source of the daily hassle than it is to let the stressor go unchecked and simply try to manage the negative emotions produced by the event. Conversely, given a stressor one cannot alter, it is more functional to regulate the emotions produced by the event than to engage in repeated futile attempts to change an uncontrollable stressor. It was predicted that subjects who tended to violate these principles across multiple daily hassles would be characterized by the highest psychological symptomology. Although the 69 college students' frequency of daily hassles was positively associated with psychological symptomatology and students tended to match the method of coping with the appraised controllability of their daily hassles, no support for the goodness-of-fit hypothesis was found.

Adaptation, Psychological↗
PubMed1995

Improving the primary management of emergency surgical admissions: a controlled trial.

The initial screening by senior surgical staff of surgical patients referred for emergency hospital admission should result in improved patient management. The present study was undertaken to determine the effects of this policy. The primary outcome measure was hospital admission rates. The number of operations, diagnostic investigations, initial treatments, deaths, length of stay and bed days per 100 referrals were also measured. The results suggest a 20 per cent reduction in emergency surgical admissions, an important potential benefit to the health service, and to individual patients.

Adult↗
PubMed1994

Risk factors for development of chronic superficial keratitis in dogs.

Proportional hospital accession ratios for chronic superficial keratitis (CSK) of dogs were determined for 16 US veterinary teaching hospitals participating in the Veterinary Medical Data Base between Jan 1, 1976 and Dec 31, 1991. The prevalence of CSK was significantly correlated (r = 0.90) with altitude of residence, but not with latitude, longitude, mean annual solar radiation, or mean annual relative humidity. Medical records of dogs with (n = 595) and without (n = 72,877) CSK examined at the Colorado State University Veterinary Teaching Hospital between Jan 1, 1976 and Oct 28, 1991 were also reviewed. Belgian Tervuren, German Shepherd Dogs, Border Collies, Greyhounds, Siberian Huskies, and Australian Shepherds were disproportionately affected. Dogs between 4 and 7 years old were 2.36 times more likely to develop lesions than were dogs < 4 years old (P < 0.05). Among dogs < 4 years old, spayed females, sexually intact males, and castrated males were more likely to develop the condition (P < 0.05) than were sexually intact females. Altitude of residence was a significant risk factor in the development of CSK among dogs in Colorado. Dogs living at altitudes > 7,000 ft above sea level were 7.75 times more likely to develop lesions than were dogs living at elevations between 3,000 and 5,000 ft.

Age Factors↗
PubMed1994

The EPC approach to estimating safety from exposure to environmental chemicals.

Reference doses (RfDs) and reference concentrations (RfCs) developed by the United States Environmental Protection Agency (USEPA) are typically used in the quantitation of risk of potential adverse human health effects from exposure to environmental chemicals. For a large number of chemicals, however, USEPA RfDs and RfCs have not yet been determined. Thus, for risk assessments that involve a large number of chemicals, there is insufficient toxicity information with which to evaluate potential adverse human health effects for all chemicals present at a particular site. Due to this insufficiency, the risk assessor must either (1) ignore potential exposures on the assumption that omitting these exposures does not significantly alter decisions concerning the remediation of the site or (2) undertake a lengthy and costly analysis to generate the necessary RfDs or RfCs. A potential solution to this problem is to develop estimated permissible concentrations (EPCs), values which represent permissible environmental concentrations or related acceptable daily dosages derived from occupational exposure limits. In the present analysis, acceptable daily dosages determined using the EPC method were compared to USEPA RfDs or RfCs which were converted to dosages based on standard exposure assumptions. Based on a comparative analysis of EPCs and USEPA reference values for 103 chemicals, it was found that EPC daily dosages represent a reasonably conservative surrogate value when USEPA or state reference values are unavailable. Given that there are hundreds of chemicals with occupational exposure limits but no state or USEPA reference values, acceptance of the EPC methodology would provide an interim solution for the problem of insufficient toxicity information for a substantial number of environmental chemical contaminants.

Animals↗
PubMed1994

Methylphenidate-induced hepatotoxicity in mice and its potentiation by beta-adrenergic agonist drugs.

Methylphenidate hydrochloride, when administered as a single 75 to 100 mg/kg i.p. dose, was found to produce hepatic necrosis in male ICR mice. Peak hepatotoxicity, as measured by serum ALT elevations, occurred 16 hours post-treatment while maximal histopathological evidence of hepatotoxicity occurred 24-48 hours after the methylphenidate dose. Liver injury measured by either method was essentially nonexistent for dosages < or = 50 mg/kg in male mice, and was only minimally evident in female mice at the highest dosage testable. Co-treatment of mice with either alpha 1- or alpha 2-adrenergic agonist drugs had no meaningful effect on methylphenidate-induced hepatotoxicity. In contrast, the beta-adrenergic agonist drug isoproterenol produced a striking potentiation of the liver injury, and shifted the apparent threshold for toxicity approximately 5- to 10-fold. Co-administration of methylphenidate with the mixed alpha/beta-adrenergic agonist dobutamine or with the beta 2-selective agonists metaproterenol, ritodrine or terbutaline produced a similar potentiation of toxicity. Parallel tests with beta-adrenergic antagonists revealed that the potentiation by isoproterenol could be significantly diminished by a single dose of the non-selective beta-adrenoreceptor blocking drug nadolol or the beta 2-selective antagonist ICI-118,551, but not the beta 1-selective antagonist metoprolol. Collectively, these observations suggest that potentiation of methylphenidate hepatotoxicity occurs through stimulation of beta 2-adrenoreceptors. Mice co-treated with isoproterenol were found to have substantially higher serum and liver methylphenidate levels following the methylphenidate dose, and significant increases were also observed in the area-under-the-curve (AUC) for methylphenidate in both tissues of isoproterenol co-treated mice. The results of this study suggest that beta 2-adrenergic agonist drugs are capable of potentiating methylphenidate-induced hepatotoxicity in mice by increasing hepatic methylphenidate concentrations.

Adrenergic alpha-Agonists↗
PubMed1994

Enzyme-catalysed kinetic resolution of 4-endo-hydroxy-2-oxabicyclo[3.3.0]oct-7-en-3-one and employment of the pure enantiomers for the synthesis of anti-viral and hypocholestemic agents.

The endo-hydroxylactone (+/-)-(1) was resolved by enantioselective acetylation using Candida cylindracea lipase or preferentially Pseudomonas fluorescens lipase (pfl). Alternatively the corresponding butyrate (+/-)-(3) was hydrolysed with pfl to give the ester (+)-(1S,4R,5S)-(3) and the alcohol (-)-(1R,4S,5R)-(1). The latter compound was converted into carbovir (-)-(1R,4S)-(12) while the ester (+)-(3) was transformed into the delta-lactone (+)-(3R,5S)-(18). The exo-hydroxylactone (+/-)-(2) was resolved less efficiently by a trans-esterification process employing pfl and vinyl acetate.

Anticholesteremic Agents↗
PubMed1994

Microbial hydrolysis of glutaronitrile derivatives with Brevibacterium sp. R 312.

The enantiomerically pure (S)-cyano acids 3 and 4 can be obtained by biotransformation with Brevibacterium sp. R 312 of the corresponding prochiral dinitriles 5 and 6, respectively. The hydrolysis is probably a two step process involving a nitrile hydratase and an amidase. In connection with these investigations a facile method for the synthesis of racemic 4-cyano-3-hydroxybutanoic acid derivatives was developed.

Amidohydrolases↗
PubMed1994

The Saccharomyces cerevisiae SPT8 gene encodes a very acidic protein that is functionally related to SPT3 and TATA-binding protein.

Mutations in the Saccharomyces cerevisiae SPT8 gene were previously isolated as suppressors of retrotransposon insertion mutations in the 5' regions of the HIS4 and LYS2 genes. Mutations in SPT8 confer phenotypes similar to those caused by particular mutations in SPT15, which encodes the TATA-binding protein (TBP). These phenotypes are also similar to those caused by mutations in the SPT3 gene, which encodes a protein that directly interacts with TBP. We have now cloned and sequenced the SPT8 gene and have shown that it encodes a predicted protein of 602 amino acids with an extremely acidic amino terminus. In addition, the predicted SPT8 amino acid sequence contains one copy of a sequence motif found in multiple copies in a number of other eukaryotic proteins, including the beta subunit of heterotrimeric G proteins. To investigate further the relationship between SPT8, SPT3 and TBP, we have analyzed the effect of an spt8 null mutation in combination with different spt3 and spt15 mutations. This genetic analysis has shown that an spt8 deletion mutation is suppressed by particular spt3 alleles. Taken together with previous results, these data suggest that the SPT8 protein is required, directly or indirectly, for TBP function at particular promoters and that the role of SPT8 may be to promote a functional interaction between SPT3 and TBP.

Amino Acid Sequence↗
PubMed1994

Methamphetamine potentiation of carbon tetrachloride hepatotoxicity in mice.

Previous studies have indicated that adrenergic agents may potentiate the hepatotoxicity of compounds such as CCl4. Methamphetamine is a powerful central nervous system stimulating drug which also possesses significant adrenergic activity, and its effects on CCl4 hepatotoxicity were examined in male ICR mice. Cotreatment of mice with methamphetamine (15 mg/kg i.p.) resulted in a significant increase in the hepatocellular necrosis produced by minimally toxic to moderately toxic doses of CCl4 (0.005-0.02 ml/kg i.p.), as indicated by changes in serum alanine aminotransferase activity and by histopathologic examination. Methamphetamine alone at this dosage was not hepatotoxic. The ability of methamphetamine to potentiate CCl4 hepatotoxicity was dose-related and became statistically significant at methamphetamine doses of 10 mg/kg or greater. Pretreatment of animals with either the selective alpha-1 adrenoreceptor antagonist prazosin (5 mg/kg i.p.) or the selective alpha-2 adrenoreceptor antagonist yohimbine (5 mg/kg i.p.) blocked the methamphetamine potentiation. The increase in CCl4 toxicity produced by methamphetamine was not associated with an increase in hepatic concentrations of either CCl4 or one of its major metabolites, chloroform. The increase in toxicity was associated, however, with increases in the in vivo covalent binding of radiolabeled CCl4 to both hepatic proteins and lipids. The cause of the increased covalent binding was not identified, but did not appear to be related to methamphetamine-induced hepatic glutathione suppression. The results of this study suggest that methamphetamine potentiates CCl4 through an adrenoreceptor-related mechanism that may involve either the increased production or diminished conjugation of the reactive metabolites normally formed during the metabolism of CCl4.

Alanine Transaminase↗
PubMed1993

Use of orbital implants after enucleation in dogs, horses, and cats: 161 cases (1980-1990).

Eye enucleations performed on 109 dogs, 29 horses, and 23 cats involved placement of 136 silicone orbital implants and 7 mesh implants. Mean follow-up times were 2.4 years (range, 3 weeks to 9 years) in dogs, 3.4 years (range, 10 days to 10.5 years) in horses, and 1.5 years (range, 3 weeks to 7.5 years) in cats. Implants failed in 1 of 96 dogs (1.04%), 3 of 29 horses (10.3%), and 3 of 18 cats (16.7%). Implant failure was attributable to various causes in all species; however, cats appeared to be more prone to late extrusion that were dogs and horses. Implantation of an orbital prosthesis was a safe and inexpensive method for improving cosmetic appearance after enucleation in dogs, horses, and cats.

Animals↗
PubMed1993

Phenylpropanolamine potentiation of acetaminophen-induced hepatotoxicity: evidence for a glutathione-dependent mechanism.

Pretreatment of male ICR mice with the adrenergic agonist phenylpropanolamine (200 mg/kg, ip) resulted in a marked potentiation of hepatotoxicity produced by acetaminophen (400 mg/kg, ip). Enhanced liver necrosis with phenylpropanolamine pretreatment was evident both by measurement of serum aminotransferase activity and by histopathologic examination. Several lines of experimental evidence suggest this interaction is a result of the hepatic glutathione depression produced by alpha-adrenergic compounds, which adds to the glutathione depression caused by toxic, or nearly toxic, doses of acetaminophen. First, the potentiation of acetaminophen hepatotoxicity was time-dependent, being observed only when phenylpropanolamine was administered as a 3-hr pretreatment and not when given 1 hr before, with, or 3 hr after acetaminophen. The 3-hr interval between phenylpropanolamine and acetaminophen doses corresponds to the characteristic lag period required for alpha-adrenergic agents (including phenylpropanolamine) to produce significant and maximal effects on hepatic glutathione content. Second, dose-response relationships for phenylpropanolamine and acetaminophen were such that increased toxicity was observed only when the interaction was sufficient to lower hepatic glutathione concentrations below a level regarded as critical in preventing acetaminophen-induced hepatotoxicity. Third, when animals were pretreated with two nonadrenergic depletors of hepatic glutathione, diethylmaleate (125 mg/kg, ip) or the glutathione synthesis inhibitor buthionine sulfoximine (222 mg/kg, ip), at doses producing glutathione depletion approximating that observed with the adrenergic agents, acetaminophen hepatotoxicity was potentiated to the same extent. From these observations it is postulated that a variety of adrenergic compounds known to deplete hepatic glutathione by a moderate 30-50% may potentiate the hepatotoxicity of acetaminophen and possibly other hepatotoxic compounds for which glutathione conjugation is an important detoxification pathway.

Acetaminophen↗